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A biological function based
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process
Min Young Lee, Taek-Kyun Kim, Kathie-Anne Walters & Kai Wang
Implementation of multi-gene biomarker panels identified from high throughput data, including
microarray or next generation sequencing, need to be adapted to a platform suitable in a clinical setting
such as quantitative polymerase chain reaction. However, technical challenges when transitioning
from one measurement platform to another, such as inconsistent measurement results can affect
panel development. We describe a process to overcome the challenges by replacing poor performing
genes during platform transition and reducing the number of features without impacting classification
performance. This approach assumes that a diagnostic panel reflects the effect of dysregulated
biological processes associated with a disease, and genes involved in the same biological processes and
coordinately affected by a disease share a similar discriminatory power. The utility of this optimization
process was assessed using a published sepsis diagnostic panel. Substitution of more than half of the
genes and/or reducing genes based on biological processes did not negatively affect the performance
of the sepsis diagnostic panel. Our results suggest a systematic gene substitution and reduction
process based on biological function can be used to alleviate the challenges associated with clinical
development of biomarker panels.
Multi-gene biomarker panels identified from gene expression data can be used to diagnose diseases and/or stratify patients into different disease stages. Machine learning and data mining algorithms have been adapted to
identify biomarker candidates. The general workflow for transcript-based biomarker panel discovery includes
identifying disease-affected genes (e.g. differentially expressed genes), selecting a subset of genes (features) for
the panel, and building a classifier (decision rule) based on the selected features. Various feature selection methods (recursive feature elimination (RFE), least absolute shrinkage and selection operator (LASSO) method, and
the Boruta and Vita approaches) have been used1–3 by considering feature decencies and interaction with classification methods such as support vector machine (SVM), logistic regression (LR), and random forest (RF)
that have been widely applied to build diagnostic panels to discriminate between states4. Based on this general
approach, many biomarker panels have been reported in the literature but few have been successfully developed into clinical assays5,6. In part, this is due to the technical difficulties during the transition from discovery
to development phase. To implement transcript based biomarkers that were identified from high-throughput
transcriptomic data such as microarray or next generation sequencing (NGS), the transcripts (features) need
to be measured with a platform that is more suitable for use in a clinical setting such as quantitative polymerase
chain reaction (qPCR)7,8. However, there are technical challenges when moving from high-throughput platforms
into different measurement methods like qPCR. A major issue is the inconsistency of results between different
measurement platforms9–11. It is also a challenge to develop a panel with 30 or 40 features for clinical use due to
cost and implementation12.
To identify a candidate biomarker panel with a limited number of features, Top Scoring Pair (TSP) is potentially useful13. The goal of TSP is to identify a pair of genes where the ordering (i.e. the relative expression) of two
genes is reversed between groups. TSP is then extended to kTSP, k pairs of genes, to achieve a higher performance
through additional pairs of genes14. To address the inconsistency between measurement platforms15, demonstrated that poor performing features (genes) in a 17 gene panel for predicting clinical outcome of breast cancer
patients can be substituted with highly correlated genes in the same pathway15. Additionally, the authors showed
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Figure 1. Identification of substitutes for Stanford11. (A) The overall procedure of the identification of
substitutes for Stanford11. (B) The six key biological processes represented by the Stanford11 panel.
that the number of features in the panel can be reduced, although the original 17 gene panel remained the best
predictor.
In this study, we describe a systematic process to optimize transcript based biomarker panels by both replacing
poor performing genes (features) and reducing the number of features in the panel. The approach is based on the
similar hypothesis described by Liu et al. in that a diagnostic panel measures the combined effect of dysregulated
biological processes during the development of a disease and that highly correlated genes involved in the same
biological processes should share similar discriminatory power. We further filtered substitution candidates by
selecting those that have the same directional changes of its concentrations in the disease, rather than simply
the highest correlated gene. The complex regulatory network in a biological system coordinately affects multiple
genes relating to the phenotype that can be equivalent to each other for discriminating the phenotype16. This
biological function-based gene substitution provides a solution for gene measurement issues encountered during
platform transition. Our approach can also be used to reduce the features in a diagnostic panel by identifying a
minimal set of genes to represent core biological processes in a multi-gene biomarker panel.
The utility of the biomarker optimization process was demonstrated using a published sepsis diagnostic panel,
referred to here as the Stanford11 gene panel17. We investigated (1) critical biological pathways associated with the
Stanford11 gene panel, (2) the impact of gene substitution on the diagnostic performance of the Stanford11 gene
panel, and (3) minimal core genes required for the diagnostic panel. We showed that substitution and reduction
of more than half of the Stanford11 does not affect the performance. Multiple alternative panels with less features
compared to the Stanford11 were identified, but have equivalent diagnostic performance. The results suggest a
systematic gene substitution and reduction process can be used to alleviate the challenges associated with translation of candidate biomarker panels into clinically applicable assays without sacrificing the performance of a
biomarker panel.

Results

Identification of substitutable genes for the Stanford11 sepsis diagnosis panel. The overall pro-

cedure and the results of identifying substitutable genes for Stanford11 are summarized in Fig. 1A. There were
503 gene ontology biological processes (GOBPs) represented by at least one of the 82 differentially expressed
genes (DEGs) termed Stanford82. The genes in the Stanford11 panel were involved in 97 different GOBPs, with
the exception of ZDHHC19 and KIAA1370 which are not associated with known biological function. Among
the 97 GOBPs associated with Stanford11, 27 of them had at least one additional gene from the Stanford82 gene
pool that is not in the Stanford11 panel and can be used as potential substitution candidates. These 27 GOBPs
are represented by six key biological processes; (1) chemotaxis, adhesion, migration; (2) antigen processing,
immune response; (3) transcription by pol II; (4) platelet activation; (5) apoptosis; and (6) metabolism (Fig. 1B).
We summarized substitution candidates that are involved in these 6 key biological processes associated with
the Stanford11 panel (Table 1). Among the six key biological processes, two processes, chemotaxis, adhesion,
migration and platelet activation, have more than two genes in the panel and the remaining four processes have
just one gene. RPGRIP1, a gene associated with neural precursor cell proliferation and retina development, is
substitutable only with the genes already included in the Stanford11 panel and so was excluded for gene substitution. Among the substitutable genes, only genes with the same directional changes as genes in the Stanford11
panel, i.e., increased or decreased expression level in sepsis patients compared to controls were selected. Among

Scientific Reports |

(2019) 9:7365 | https://doi.org/10.1038/s41598-019-43779-2

2

www.nature.com/scientificreports

www.nature.com/scientificreports/
Chemotaxis, adhesion,
migration

CEACAM1↑

ADAMTS3↑,
CCR1↑,
CD177↑,
CD63↑,
EMR1↑,
FCER1G↑,
IL10↑,
OSTalpha↑,
PSTPIP2↑,
SIGLEC9↑,
TBC1D4↓

C3AR1↑

ANXA3↑,
CCR1↑,
CD177↑,
EMR1↑,
FCER1G↑,
FES↑,
FFAR3↑,
IL10↑,
S100A12↑

TGFBI↓

CCR1↑,
EMR1↑,
FES↑,
SIGLEC9↑

GNA15↑

CCR1↑,
EMR1↑,
FFAR3↑

HLA-DPB1↓

Antigen processing,
immune response

Transcription
by RNA pol II

Platelet
activation

Apoptosis

Metabolism

GPR84↑

FCER1G↑,
P2RX1↑
BPI↑, CCR1↑,
FCER1G↑,
FCGR1B↑,
IL10↑,
IL18R1↑

BATF↑

MTCH1↓
C9orf95↑

IL10↑,
PLAC8↑,
GLO1↓,
PRKRIR↓,
WDR75↓
LCN2↑,
OSTalpha↑,
P2RX1↑,
ARHGEF18↓
C9orf103↑,
SEPHS2↑

Table 1. The list of substitutable genes for features in the Stanford11. Substitution candidates (n = 28) for
eight genes of Stanford11 were selected based on six key biological processes. ↑ And ↓ indicates increased or
decreased expression level in sepsis, respectively. No substitutable gene was retained for TGFBI and HLA-DPB1
after considering consistency in directional changes.

the 28 substitution candidates, 20 genes were retained for six genes in the Stanford11 panel (CEACAM1, C3AR1,
GNA15, BATF, MTCH1, and C9orf95) representing five biological functions. TGFBI (GOBP chemotaxis, angiogenesis, adhesion, migration) was removed since no substitutable gene with the same directional change was
retained. There was also no substitutable gene for HLA-DPB1 (immune response function); therefore, HLADPB1 was retained to keep all six biological processes during substitution and reduction procedures. Interestingly,
most of the six genes that can be substituted in the Stanford11 panel showed increased expression level in sepsis
patients except MTCH1, a gene involved in apoptosis (Table 1).
Since three genes (ZDHHC19, KIAA1370, and RPGRIP1) were excluded during the process of identification
of substitutable genes, their contribution to the classification performance (defined as area under the curve, AUC)
of Stanford11 was assessed. Interestingly, excluding these genes from Stanford11 did not significantly affect the
performance in both discovery and validation sets (Supplementary Table S3). In the case of excluding all three
genes, the performance decreased in one discovery and one validation set (Glue grant day [1–3] from 0.9145 to
0.865 and GSE74224 from 0.8814 to 0.8544) while increasing in one discovery set (GSE40012 from 0.7091 to
0.774). Therefore, the three genes contributed marginally to the diagnostic performance of Stanford11.

Importance of biological processes on classification performance. To determine the impact of bio-

logical processes in the performance of a diagnostic panel, we generated 100,000 panels consisting of 11 genes
randomly selected from the Stanford82 list. The classification performances of the 100,000 random 11 member
gene sets in the nine discovery datasets were computed and sorted based on the performance as measured by
AUC (Fig. 2A). The GOBP associated with genes in the top 250 and bottom 250 gene sets were summarized
in Fig. 2B. The GOBPs represented by the top 250 gene sets were similar to the Stanford11 six key processes
(Fig. 2B), such as transcription by pol II (cluster 1 and 2 in Fig. 2B,C), phosphorylation (cluster 4), apoptosis
(cluster 5), PLC (cluster 6), chemotaxis (cluster 7), antigen processing and presentation (cluster 11), metabolic
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Figure 2. Importance of biological processes on classification performance. (A) The distribution of
classification performances of the 100,000 random gene sets. (B) The number of genes of the top and bottom
250 gene sets in 97 GOBPs represented by Stanford11. (C) Clusters of GOBPs in the top 250 and bottom 250
gene sets. Count and percent indicate the average number and percentage of genes in each GOBP cluster.

process (cluster 13). Interestingly, the neural precursor cell proliferation and retina development process in cluster 3 was also frequently involved in high performing gene sets. RPGRIP1, which has no substitutable gene, was
involved in this biological process. However, removing RPGRIP1 from Stanford11 did not significantly decrease
diagnostic performances as shown in Supplementary Table S3. It suggests that genes involved in this biological
process have discriminating power but are not essential to retain classification performance of gene panels.

Impact of gene substitution on classification performance. A total of 12 microarray datasets from
the public domain were used to evaluate the effect of gene substitution/reduction on the diagnostic performances
of Stanford11. Nine of the datasets were used in the original discovery of the Stanford11 gene panel. The other
three, GSE65682, GSE74224 and E-MTAB-3589, were not used in the development of Stanford11 panel; therefore, they were used as independent validation data in this study.
Based on the substitution candidates listed in Table 1, we changed one gene at a time for the six substitutable
genes in the Stanford11 panel. As shown in Fig. 3A–F, one gene substitution does not affect the overall diagnostic
performance in both the nine discovery and three validation datasets. In discovery datasets, the average AUCs
of the substitutions were not significantly lower than the original Stanford11 panel except using the GSE74224
dataset when replacing GNA15 (Fig. 3E).
We then tested the effect of substituting genes representing all functional categories simultaneously. If a function had more than one substitutable gene, all combinations of genes were enumerated and their classification
performances were tested and summarized in Fig. 4. Except for the GSE40012 and GSE66099 datasets used in
the Stanford11 discovery process, there were multiple five gene substitutions that showed similar performances
as the original Stanford11. In summary, gene substitution based on the same biological process and direction of
concentration changes can provide alternative panels that have similar diagnostic performance.
Impact of gene reduction on classification performance. The possibility of using representative genes

from each biological process to reduce the number of features in the diagnostic panel was investigated. Among
the six representative biological processes of the Stanford11 panel, two biological functions have more than one
gene in the panel. The GOBP, “platelet activation function” has two genes (C3AR1 and GNA15) and “chemotaxis,
adhesion, migration function” has four genes (CEACAM1, C3AR1, TGFBI, and GNA15) in the panel. The AUCs
of panels where only one gene was retained were calculated. As shown in Fig. 5A, the two panels with only one
gene retained from “platelet activation function” have similar performance to the Stanford11. The panels with
only one gene from the GOBP “chemotaxis, adhesion, migration function” also have similar performance in the
datasets used to identify Stanford11 (Fig. 5B). The impact of retaining only one gene from both GOPBs was tested
and the average diagnostic performance was not significantly different from the original Stanford11 panel in all
the discovery and validation sets (Fig. 5C). In all cases, there were multiple panels with reduced features that
delivered better performances in more than half of the independent validation datasets.
To explore the possibility of just using representative genes from key biological processes associated with
Stanford11, all possible combinations of six gene panels were generated from genes mapped to those six biological
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Figure 3. The performances of one gene substitution. The distribution of AUCs in the 12 microarray datasets
when (A) BATF; (B) C3AR1; (C) C9orf95; (D) CEACAM1; (E) GNA15; (F) MTCH1 was replaced with a
substitute gene. *Indicates P-value from DeLong test comparing a substituted panel (blue bars) with the median
AUC and the original Stanford11 (gray bars) less than 0.05.

Figure 4. The performances of five gene substitution. The AUCs in the 12 microarray datasets when genes
representing all five functional categories were replaced with substitute genes. *and **indicate P-value from
DeLong test comparing a substituted panel with the median AUC and the original Stanford11 less than 0.05 and
0.01, respectively.

processes. Diagnostic performances for all six-gene combinations were computed (Fig. 6). Among the 1,482
six-gene combinations, 73 new panels which have higher performance than the lower bound of 95% confidence
intervals in all discovery datasets than the original panel were selected (Supplementary Table S4). Among the
73 new panels, 22 panels have higher performance even in the two validation sets (GSE65682 and GSE74224,
Table 2).

Addition of RPGRIP1 to the new six-gene panels. Though removing RPGRIP1 (neural precursor cell
proliferation and retina development process) from the original Stanford11 panel did not decrease the overall
diagnostic performance (Supplementary Table S3), we tested the effect of adding RPGRIP1 to the new 6 gene
panels. The results showed that adding RPGRIP1 to the 6-gene panel only improved the performance in one of
the validation datasets, GSE74224, but not in the other two datasets (Supplementary Table S5).
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Figure 5. The performances of gene reduction. The AUCs in the 12 microarray datasets when only one gene
in (A) platelet activation function; in (B) chemotaxis, adhesion, migration function; (C) in both processes was
retained. *and **indicate P-value from DeLong test comparing a substituted panel with the median AUC and
the original Stanford11 less than 0.05 and 0.01, respectively.

Figure 6. The performances of 1,482 six-gene combinations. *and **indicate P-value from DeLong test
comparing a substituted panel with the median AUC and the original Stanford11 less than 0.05 and 0.01,
respectively.

Evaluation of the impact of biological function information. The performance differences between
biological function-based and expression correlation-based substitution were tested. Based on expression profiles
of all the discovery datasets, the highest correlated genes with features in the Stanford11 were selected (referred
to as Panel-HC) regardless of the biological functions (Table 3). Most of the highest correlated genes with features
in the Stanford11 were not from Stanford82 nor involved in the same GOBPs represented by Stanford11. For
instance, BATF of Stanford11 is involved in transcription by pol II, but the highest correlated gene, DDAH2 is
involved in nitric oxide biosynthetic process. The average AUCs of the Panel-HC in the discovery and validation
sets were 0.8238 and 0.6846 which are 3.58% and 14.40% lower than the Stanford11 (average AUC of 0.8544 and
0.7997 in the discovery and validation sets, respectively (Fig. 7A). This suggests maintaining biological processes
associated with disease condition is more critical to generating high performance diagnostic panels than maintaining features with highly correlated expression profiles.
By randomly selecting 11 out of 14 genes involved in adhesion/migration process, 364 panels were generated
(referred to as Panel-AM) (Table 3). The performances of Panel-AM were also lower than Stanford11 (average
AUC of 0.7999 and 0.7546 in the discovery and validation sets, respectively, Fig. 7B) which suggests genes from
one biological process do not deliver sufficient diagnostic performance.
We further test the feasibility of using existing algorithms to optimize the panel. Among various wrapper
approaches, SVM-RFE and LR-LASSO were applied. Ten (referred to here as the Panel-SVM) and six genes
(Panel-LR) were obtained from the Stanford11 genes by the SVM-RFE and LR-LASSO approaches, respectively (Table 3). The classification performance of the two panels was not significantly different from the original
Stanford 11 panel (Fig. 7C,D). The SVM-RFE approach did not effectively reduce the number of genes in the
panel. The LR-LASSO resulted in a 6 gene panel with similar performance as original Stanford11 panel; therefore, it might be a useful approach to optimize gene panels. However, both approaches can only down-select
genes from an existing panel and cannot provide any substitutable genes if any of the original genes fails in assay
development process. kTSP algorithms were also applied to identify classifiers with a small set of paired genes.
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6-gene
Panels

Chemotaxis,
adhesion,
migration

Antigen
processing,
immune response

Transcription by
RNA pol II

Platelet
activation

Apoptosis

Metabolism

GSE65682

GSE74224

E-MEXP-3589

1

CCR1

HLA-DPB1

BATF

C3AR1

ARHGEF18

C9orf95

0.7807

0.8854

0.6633

2

CCR1

HLA-DPB1

BATF

C3AR1

MTCH1

C9orf103

0.8170

0.9058

0.6990

3

CCR1

HLA-DPB1

BATF

C3AR1

MTCH1

C9orf95

0.8095

0.8967

0.6786

4

CCR1

HLA-DPB1

BATF

GNA15

MTCH1

C9orf95

0.8080

0.8893

0.6378

5

CD177

HLA-DPB1

BATF

C3AR1

MTCH1

C9orf95

0.8014

0.8827

0.6684

6

CD63

HLA-DPB1

PLAC8

FCER1G

MTCH1

C9orf95

0.8158

0.9128

0.6122

7

CD63

HLA-DPB1

PLAC8

GNA15

ARHGEF18

C9orf95

0.7852

0.9220

0.5663

8

CD63

HLA-DPB1

PLAC8

GNA15

MTCH1

C9orf95

0.8107

0.9333

0.5918

9

CD63

HLA-DPB1

BATF

C3AR1

MTCH1

C9orf95

0.8080

0.9067

0.6633

10

CD63

HLA-DPB1

BATF

GNA15

MTCH1

C9orf95

0.8029

0.8915

0.6378

11

EMR1

HLA-DPB1

BATF

C3AR1

MTCH1

C9orf95

0.8149

0.8963

0.6582

12

EMR1

HLA-DPB1

BATF

GNA15

MTCH1

C9orf95

0.8044

0.8836

0.6071

13

FCER1G

HLA-DPB1

PLAC8

C3AR1

MTCH1

C9orf95

0.8080

0.9241

0.6531

14

FCER1G

HLA-DPB1

PLAC8

GNA15

ARHGEF18

C9orf95

0.7861

0.9098

0.5408

15

FCER1G

HLA-DPB1

PLAC8

GNA15

MTCH1

C9orf95

0.8092

0.9185

0.5816

16

FCER1G

HLA-DPB1

BATF

C3AR1

MTCH1

SEPHS2

0.8086

0.8867

0.6582

17

FCER1G

HLA-DPB1

BATF

C3AR1

MTCH1

C9orf95

0.8071

0.8963

0.6480

18

FES

HLA-DPB1

PLAC8

FCER1G

MTCH1

C9orf95

0.8089

0.8945

0.6173

19

FES

HLA-DPB1

PLAC8

GNA15

ARHGEF18

C9orf103

0.7870

0.9098

0.6122

20

FES

HLA-DPB1

PLAC8

GNA15

MTCH1

C9orf95

0.8005

0.9150

0.6071

21

FES

HLA-DPB1

BATF

C3AR1

MTCH1

C9orf95

0.8026

0.8806

0.6786

22

C3AR1

HLA-DPB1

BATF

GNA15

MTCH1

C9orf95

0.7999

0.9133

0.6480

Table 2. Optimized six-gene panels (n = 22) with higher performance in the validation sets. Among six gene
panels (n = 73) that have higher performance than the lower bound of 95% confidence intervals of the original
Stanford11 panel in all discovery datasets, 22 panels have even higher performance in two independent datasets.

The 11 highest correlated genes
Stanford11

Panel-HC

CC

BATF

DDAH2

0.7642

Stanford
82

C3AR1

SQRDL

0.5393 √

C9orf95

PTPN22

0.4870

CEACAM1

GPR84

0.8169 √

GNA15

FERMT3

0.5874

ZDHHC19

GPR84

0.7408 √

HLA-DPB1

HLA-DMB

0.7329

KIAA1370

KIAA1468

0.6517

MTCH1

CDK5RAP3 0.6607

RPGRIP1

NOV

0.5266

TGFBI

CPVL

0.8078

Chemotaxis, adhesion,
migration processes

SVM-RFE

LR-LASSO

k-Top Scoring
Pairs

14 genes

10 genes

6 genes

6 genes

C3AR1, CD177, FCER1G,
CEACAM1, ADGRE1,
CCR1, TGFBI, SIGLEC9,
CD63, PSTPIP2, FES,
ANXA3, IL10, RETN

BATF, TGFBI, GNA15,
C9orf95, MTCH1,
C3AR1, ZDHHC19,
KIAA1370, RPGRIP1,
CEACAM1

BATF, C3AR1,
C9orf95,
GNA15,
MTCH1,
TGFBI

TGFBI - C3AR1
GNA15 CEACAM1
RPGRIP1 ZDHHC19

Table 3. Genes used in evaluation of the impact of biological function information. √ in Stanford82 column
indicates the genes of Stanford82. CC indicates the Pearson’s correlation coefficient between the genes.
It resulted in three pairs which including six genes in total (referred to as Panel-kTSP, Table 3). The Panel-kTSP
showed significantly lower performance in independent datasets (AUC < 0.6 and p-value from DeLong’s test of
less than 0.01 in two validation data sets in Fig. 7E). Therefore, the kTSP approach failed to provide a panel with
good classification performance. In addition, similar to the SVM-RFE and LR-LASSO approaches, kTSP cannot
provide alternative genes.

Discussion

There are two main considerations when validating and developing a biomarker panel: (1) the measurement
inconsistency when transitioning from one measurement platform (for example, microarray) to another (such
as qPCR), and (2) the number of features in the panel. Neither revisiting the discovery phase (identifying DEGs,
feature selection, and using different computational approaches) to generate new panel(s) nor examining all possible combinations of DEGs already discovered can overcome these challenges. In the case of Stanford11 panel, to
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Figure 7. Evaluation of the impact of biological function information. The importance of biological function
information was evaluated in five different approaches. (A) The AUCs of the Panel-HC. (B) The AUCs of the
Panel-AM. (C) The AUCs of the Panel-SVM. (D) The AUCs of the Panel-LR. (E) The AUCs of the Panel-kTSP.
*and **indicate p-value from DeLong test less than 0.05 and 0.01, respectively.

identify alternative 11 gene panels from the Stanford82 is computationally challenging, since there are 1.4e + 13
possible combinations of 11 gene panels from the Stanford82 genes. To assess the performance of these panels
would take 32,407 days even on a 100 node cluster computer (based on estimated calculation time per one combination for 12 datasets: 0.02 seconds). To address these challenges, we used a systematic process to reduce the
number of features and to replace poor performing genes in the panel with other differentially expressed genes
with similar biological function. The fact that features are substitutable, based on similar trend of expression
changes and biological function, leads to the conclusion that the performance of a biomarker panel has more
to do with its connection to disease-perturbed networks than to the specific genes themselves. The result of this
feature substitution method is a number of different panels comprising only six genes, with performances at least
as high as the original 11 gene panel.
There has been a discussion on the multiplicity of disease signatures16,18. Different computational and mathematical algorithms, noisy measurements, and/or different data pre-processing procedures result in different
molecular signatures. Some studies also suggested that overfitting and/or artifacts from data analyses also yield
different molecular signatures19. On the other hand, others have proposed that the multiplicity attributes to the
complex regulatory networks of the biological system leading to multiple biomarker sets that are equally predictive. Statnikov et al. showed that numerous signatures can be identified regardless of microarray platforms,
pre-processing methods, and model algorithms suggesting that intrinsic gene-gene and gene-phenotype relations
might be a source of multiplicity16. Our results also support this hypothesis by showing that genes involved in the
same biological process are interchangeable and share similar discriminatory power.
In conclusion, this study showed a multigene biomarker panel can be optimized through systemic gene substitution and reduction based on biological function information. The method outlined here can be applied to
identify alternative panels for other multigene/protein based biomarkers for numerous diseases and may facilitate
developing clinically applicable assays by alleviating challenges in transitioning from high-throughput measurement platform to other platforms.

Methods

Sepsis MetaScore. The Stanford11 gene panel (CEACAM1, ZDHHC19, C9orf95, GNA15, BATF, C3AR1,
KIAA1370, TGFBI, MTCH1, RPGRIP1, and HLA-DPB1) was developed by first identifying 82 differentially
expressed genes (DEGs) termed Stanford82 (Supplementary Table S2), from a meta-analysis of nine independent
microarray datasets (Supplementary Table S1). The panel was generated using the greedy forward search method,
an algorithm to assemble biomarker panels by identifying the best gene to classify samples and sequentially adds
the next best genes to increase the classification score until maximum score is achieved. Classification of each
sample was determined based on the Sepsis MetaScore (SMS) which was calculated according to the following
equation20:
SMS =

6

(CEACAM1 × ZDHHC19 × C9orf95 × GNA15 × BATF × C3AR1)

−5/6 5 (KIAA1370 × TGFBI × MTCH1 × RPGRIP1 × HLADPB1)
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SMS is the difference between a geometric mean of up-regulated genes in sepsis and a geometric mean of
down-regulated genes in sepsis. The same equation was applied to all alternative panels generated with gene substitution and reduction procedures described below. Classification power of SMS in each dataset was determined
by the area under the curve (AUC) of receiver operating characteristic (ROC) curve. Two-sided 95% confidence
intervals for AUC were computed using pROC R package21. Statistical significance of the difference between
AUCs was computed with DeLong’s method.

Identification of substitutes for Stanford11. The list of substitutable genes in Stanford11 was generated

based on gene ontology biological processes (GOBPs). We first analyzed the biological functions associated with
the Stanford82 genes through functional enrichment analyses of GOBPs using DAVID (Database for Annotation
Visualization and Integrated Discovery)22. We used GO Direct category which provides GO mappings directly
annotated by the source database. The terms with ≥1 genes were selected as Stanford82 associated GOBPs. The
GOBPs which included at least one of Stanford11 genes and with at least 2 genes were selected and visualized as
a network using Enrichment Map v2.1.0, a Cytoscape plugin23. The connected GOBP terms were merged and
defined as a single functional category. Genes involved in the merged GOBPs and having the same directional
changes were defined as substitutable candidates in the same GOBP.

Microarray datasets. A total of 12 different microarray datasets were used in two studies by Sweeney et al.
(Supplementary Table S1)20. The first nine datasets are the discovery set that was used to identify Stanford11
and the last three datasets are independent validation sets. The microarray datasets were normalized by the
same methods used by Sweeney et al. Briefly, Affymetrix datasets were normalized using the Robust Multi-array
Average (RMA) or GC-RMA (R package affy)24. Agilent and Illumina datasets were background corrected based
on normal-exponential convolution model and then between-arrays quantile normalized using R package
limma25. The mean of multiple probes for common genes was used as the gene expression level after normalization. In the case of GSE74224, there was no probe for KIAA1370 in Stanford11; therefore, only 10 genes were used
to compute the performance of Stanford11 for this data.
Gene substitution and reduction procedure. In order to systematically evaluate the effect of gene substitution and reduction on classification performance, five different procedures were used as follows: (1) substitute
one gene at a time; (2) substitute all possible genes; (3) retain one gene for a GOBP where more than two genes are
involved; 4) reduce panel by selecting one gene in each GOBP.
Evaluation of the impact of biological function information. Five different approaches were used
to evaluate the impact of biological function based optimization process on classification performance: (1) use
the 11 highest correlated genes based on the expression profiles in the Stanford11 panel regardless of their biological functions; (2) use 11 randomly selected genes involved in chemotaxis, adhesion and migration biological
function – one of GOBP terms associated with Stanford11; (3) Support Vector Machine with Recursive Feature
Elimination (SVM-RFE)3; (4) Logistic Regression with Least Absolute Shrinkage and Selection Operator regularization (LR-LASSO)26; and (5) k-Top Scoring Pairs classifier (kTSP) using switchbox R package to identify a small
set of paired genes27. The AUC of kTSP was calculated by defining the number of votes among k pairs as a diagnostic score28. The 9 microarray data in the discovery set were co-normalized using COmbat CONormalization
Using conTrols (COCONUT) R package prior to applying SVM-RFE and LR-LASSO to remove batch effect
between different studies29. The chemotaxis, adhesion and migration GOBP terms were selected as they contain
more than 11 genes that can be fully substituted for Stanford 11 genes. We also tested the classification performance of randomly selected gene sets by generating 100,000 combinations of 11 genes randomly selected from
the Stanford82 genes. We analyzed classification performance along with biological processes of the 100,000
gene sets involved in. The top and bottom 250 gene sets in order of performance were selected. The hierarchical
clustering was applied to cluster GOBPs based on the number of genes in each GOBP from the top and bottom
250 gene sets.

Data Availability

The datasets analyzed in this study are available in the Gene Expression Omnibus (GEO) and ArrayExpress repositories. The accession numbers are included in the Supplementary Table S1. The code implementation used
for biomarker gene panel optimization was uploaded to a GitHub repository, https://github.com/taekkyun/biomarker-panel-optimization.
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